NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Rationale: Adjuvant chemotherapy after surgery significantly improved the survival of PC patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesion which are not being detected in early diseases status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant s

Trial Details

NCT ID
NCT05529940
Phase
PHASE3
Sponsor
Seoul National University Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Folfirinox
Locations (sample)
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • \- A. Age: 19 to 80 years old B. Patients with a score of 0 - 1 (ECOG) when selecting a study subject C. Pancreatic ductal adenocarcinoma diagnosed…
  • No arterial tumor contact (celiac asix, superior mesenteric artery, or common hepatic artery).
  • No tumor contact with the superior mesenteric vein or portal vein or ≤ 180°contact without vein contour irregularity.
  • E. No distant metastases on preoperative imaging F. Patients with adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →